Cargando…

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors

Epigenetic factors play important roles in tumor immunology. Histone-lysine N-methyltransferase 2 (KMT2) family genes exert histone H3 methylation, but its role in immunotherapy remains unclear. Our study is the first to investigate the correlation between KMT2 gene mutations and the clinical benefi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Rui, Wu, Hao-Xiang, Xu, Ming, Xie, Xiaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724704/ https://www.ncbi.nlm.nih.gov/pubmed/33298164 http://dx.doi.org/10.1186/s40364-020-00241-0

Ejemplares similares

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers
por: Zhang, Peng, et al.
Publicado: (2021)

Haploinsufficiency of KMT2D is sufficient to cause Kabuki syndrome and is compatible with life
por: Luperchio, Teresa Romeo, et al.
Publicado: (2019)

BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition
por: Meng, Yu, et al.
Publicado: (2023)

Targeting ERBB2 mutations in solid tumors: biological and clinical implications
por: Cousin, Sophie, et al.
Publicado: (2018)

An alternative approach to confirm mixed lineage involvement in acute leukemia with KMT2A rearrangement– an illustrative report
por: Ray, Debadrita, et al.
Publicado: (2023)

Implementation of smoking signature as an improved biomarker predicting the response to immunotherapy
por: Yang, Haitang, et al.
Publicado: (2022)

Smoking signature as a biomarker for immunotherapy
por: Li, Mengqian, et al.
Publicado: (2022)

The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome
por: Hinai, Adil S.A. Al, et al.
Publicado: (2019)

MUC4, MUC16, and TTN genes mutation correlated with prognosis, and predicted tumor mutation burden and immunotherapy efficacy in gastric cancer and pan‐cancer
por: Yang, Yue, et al.
Publicado: (2020)

Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors
por: Kovács, Szonja Anna, et al.
Publicado: (2023)

Potential Biomarkers Associated With the Nature of Uterine Benign Mesenchymal Tumors
por: Tamura, Saya, et al.
Publicado: (2022)

Comment on “Therapeutic Effects and Biomarkers in Sublingual Immunotherapy: A Review”
por: Kroker, George F., et al.
Publicado: (2012)

Outstanding outcomes in infants with KMT2Agermline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial
por: Guest, Erin M., et al.
Publicado: (2022)

Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors
por: Hayashi, Takuma, et al.
Publicado: (2019)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
por: Kim, Hana, et al.
Publicado: (2021)

Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Squamous Cell Carcinomas Identifies KMT2C as a Potential Tumor Suppressor
por: Machnicki, Marcin M., et al.
Publicado: (2022)

Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers
por: Yang, Alexander, et al.
Publicado: (2020)

Rare Gene Rearrangement t(11;22)(q23;q13)/KMT2A-EP300 in Therapy-related Acute Myeloid Leukemia: A Case Report
por: Kim, Seo Wan, et al.
Publicado: (2022)

Somatic mutations in homologous recombination pathway predict favourable prognosis after immunotherapy across multiple cancer types
por: Liu, Zaoqu, et al.
Publicado: (2021)

KMT2C mutation in a Chinese man with primary multidrug-resistant metastatic adenocarcinoma of rete testis: a case report
por: Zhang, Yue, et al.
Publicado: (2022)

Weakened humoral immune responses of inactivated SARS‐CoV‐2 vaccines in patients with solid tumors
por: Chen, Zhiwei, et al.
Publicado: (2022)

XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
por: Li, Xuanzong, et al.
Publicado: (2021)

Identification of IGF1R mutation as a novel predictor of efficacious immunotherapy in melanoma
por: Ma, Dongshen, et al.
Publicado: (2022)

Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients
por: Chen, Gaili, et al.
Publicado: (2020)

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
por: Arora, Sanjeevani, et al.
Publicado: (2019)

Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma
por: Au-Yeung, Rex K. H., et al.
Publicado: (2022)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
por: Gaidzik, Verena I., et al.
Publicado: (2023)

Immunotherapy for Solid Tumors
por: de Saint Basile, Hortense, et al.
Publicado: (2023)

A Compound Mutation (c.953C<G and c.49G<A) Aggravates Functional Impairments of C1-INH in Hep G2 Cells
por: Xu, Ying-Yang, et al.
Publicado: (2018)

Circulating exosomal tsRNAs: Potential biomarkers for large artery atherosclerotic stroke superior to plasma tsRNAs
por: Yang, Kaiying, et al.
Publicado: (2023)

Circulating Microparticles and Coagulation Profiles in Patients with Advanced Stage Solid Tumors
por: Sun, Der Sheng, et al.
Publicado: (2018)

Thirty-Two Case Reports of Synchronous Hematological Malignancy and Solid Tumor
por: Liu, Sha, et al.
Publicado: (2019)

Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis
por: Haddox, C L, et al.
Publicado: (2017)

Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic–pituitary–adrenal axis suppression
por: Mc Donald, Darran, et al.
Publicado: (2022)

Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
por: Voruz, Sophie, et al.
Publicado: (2021)

Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors
por: Dhar, Shilpa S., et al.
Publicado: (2021)

Potential Biomarker for Human Uterine Leiomyosarcoma
por: Hayashi, Takuma, et al.
Publicado: (2014)

KMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer
por: Mastoraki, Sofia, et al.
Publicado: (2020)

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors
por: Kim, Ji‐Yeon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_963g496o89fndh09t5d6vv9nfg